Bextra Articles
Australian Judge rules against Merck & Co’s Vioxx, saying the pain drug is not fit for sale
5 March 2010
US Court imposes record fine and forfeiture of $1.3 billion for Pfizer unit’s fraudulent marketing of Bextra
19 October 2009
Data on withdrawn drugs was faked; says hospital
16 March 2009
Pfizer
31 July 2006
Osteoporosis - the
26 June 2006
New drugs will drive Rx pain therapy market
5 June 2006
Licensing pivotal to pharma industry evolving strategies
19 December 2005
USA
22 August 2005
Glimmer of hope for Merck & Co's Vioxx
18 July 2005
Stock Commentary - New York
4 July 2005
Pfizer's Celebrex gains from Bextra withdrawal
30 May 2005
Pfizer suspends sales of Bextra in the UK
25 April 2005
Japan stock market week to April 18
25 April 2005
Three Bextra law suits filed against Pfizer
18 April 2005
Stock Commentary - New York
18 April 2005
Americans understand Rx risk/benefits: study
14 March 2005
Evidence for CV risks of COX-2s; NEJM report
28 February 2005
Stock Commentary - New York
28 February 2005
US FDA panel says COX-2s can be sold, OKs Vioxx' return to market?
28 February 2005
Stock Commentary - New York
14 February 2005
Pfizer agrees to Onsenal launch delay
31 January 2005
US FDA is urged to take Pfizer COX-2s off market
31 January 2005
Safety concerns over COX-2s deepen
24 January 2005
FDA says Pfizer's Celebrex/Bextra ads mislead
24 January 2005
Editor's views on "Big Pharma" in 2004
10 January 2005
UK Ministry advice on COX-2s
10 January 2005
Further doubt cast over safety of Bextra
10 January 2005
German post-Vioxx warning on COX-2s
20 December 2004
Editor's views on US HHS/FDA appointments; new UK regulatory agency
22 November 2004
Vioxx different to other COX-2s; study
22 November 2004
Stock Commentary - New York
15 November 2004
Study questions safety of Pfizer's Bextra
15 November 2004
Vioxx withdrawal will not hurt COX-2s initially, says NOP survey
8 November 2004
EMA to review COX-2 inhibitors
1 November 2004
Stock Commentary - New York
25 October 2004
Arthritis Rx ads "reach up to 75% of US patients"
4 October 2004
Tokyo pharma stocks - week to June 14
14 June 2004
Yamanouchi deal with Pfizer restructured
7 June 2004
Pfizer slams French, EU Rx price policies
24 May 2004
Pfizer's Bextra gives lower medical costs
30 June 2003
Pfizer's Bextra gives lower medical costs
30 June 2003
Yamanouchi's FY2003 operating income up 12%
26 May 2003
Pfizer gets Euro OK for COX-2 blocker Bextra
26 May 2003
Pharmacia's earnings match forecasts in 2002
24 February 2003
Update: Pharmacia's earnings match forecasts in 2002
24 February 2003
Pharmacia EPS up by 8% in 2nd-quarter
29 July 2002
Pfizer's 2nd-qtr net income rises 10%
22 July 2002
Merck & Co reconfirms 2002 guidance
17 June 2002
Pharmacia sales take a dip in first quarter
29 April 2002
Stock Commentary - Europe
22 April 2002
Pfizer 1st-qtr EPS increases 18%
22 April 2002
Stock Commentary - New York
25 March 2002
Stock Commentary - Europe
25 March 2002
Bextra is opioid-sparing in knee surgery
18 February 2002
Pharmacia 4th-qtr profits take a dip but Celebrex still selling well
11 February 2002
Stock Commentary - New York
4 February 2002
Rheumatoid arthritis market forecasts
14 January 2002
Pharmacia's product pipeline; what's in store after Celebrex?
29 November 2001
Update: Pharmacia gets US approval for Celebrex follow-up Bextra
20 November 2001
Pharmacia's second COX-2 cleared by FDA
19 November 2001
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
